According to a post on the FDA’s website, AstraZeneca’s treatment of Idiopathic Inflammatory Myopathies, anifrolumab, received orphan designation. Reference Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AZN:
- AstraZeneca says Dato-DXd ‘continued to demonstrate encouraging responses’
- AstraZeneca’s Dato-DXd shows ‘durable efficacy’ in HER2-low patients
- Guardant Health announces collaboration with AstraZeneca
- AstraZeneca reports detailed results from SERENA-2 Phase 3 trial
- AstraZeneca reports results from SERENA-2 trial